Study of Silodosin to Facilitate Passage of Urinary Stones

PHASE2CompletedINTERVENTIONAL
Enrollment

239

Participants

Timeline

Start Date

June 30, 2010

Primary Completion Date

July 31, 2012

Study Completion Date

July 31, 2012

Conditions
Ureteral CalculiKidney StonesUrolithiasis
Interventions
DRUG

silodosin

one silodosin 8 mg capsule orally, once daily, with food for up to 4 weeks

DRUG

placebo

one placebo capsule orally, once daily, with food for up to 4 weeks

Trial Locations (27)

Unknown

Watson Investigational Site, Birmingham

Watson Investigational Site, Anchorage

Watson Investigative Site, Mission Hills

Watson Investigational Site, Murrieta

Watson Investigational Site, San Diego

Watson Investigational Site, Daytona Beach

Watson Investigational Site, Gainesville

Watson Investigational Site, Orange City

Watson Investigative Site, Overland Park

Watson Investigative Site, North Kansas City

Watson Investigational Site, Hackensack

Watson Investigational Site, Mount Laurel

Watson Investigational Site, Sewell

Watson Investigational Site, Voorhees Township

Watson Investigational Site, Albany

Watson Investigational Site, Garden City

Watson Investigational Site, New York

Watson Investigational Site, Plainview

Watson Investigational Site, Syracuse

Watson Investigational Site, Cincinnati

Watson Investigational Site, Columbus

Watson Investigational Site, Bala-Cynwyd

Watson Investigational Site, Lancaster

Watson Investigational Site, Myrtle Beach

Watson Investigational Site, Dallas

Watson Investigational Site, San Antonio

Watson Investigational Site, Virginia Beach

Sponsors
All Listed Sponsors
lead

Watson Pharmaceuticals

INDUSTRY

NCT01144949 - Study of Silodosin to Facilitate Passage of Urinary Stones | Biotech Hunter | Biotech Hunter